Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer

Cell(2021)10.1016/j.cell.2020.12.031Source: DataRank Database

Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer is a research paper published in Cell (2021). On theSindex it has a DataRank of 0.814. It has been cited 227 times.

N/A

0.814DataRank · unranked

Scored on demand from live citation data

Open Access227 citations

Download PDF

Cite:

Linked data & code

geo dbgap nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 13.25)OA: bronzeTopics (65)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.814

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (37)

Jarey H. Wang ORCID,Fade Gong ORCID,William Wu ORCID,Nicholas J. Neill ORCID,Ik Sun Kim

Live enrichment

PubMed:33450205 PMC:PMC8635244 OpenAlex:https://openalex.org/W3119554079

NCI NIH HHS

Grant: P30 CA125123

NCI NIH HHS

Grant: U01 CA214125

NCI NIH HHS

Grant: R01 CA215226

NIDDK NIH HHS

Grant: P30 DK056338

NIGMS NIH HHS

Grant: T32 GM120011

NCI NIH HHS

Grant: R01 CA215452

Cancer Research UK

Grant: 27144

Cancer Research UK

Grant: C5470/A27144

NIGMS NIH HHS

Grant: R01 GM082837

National Institutes of Health

FWCI

13.25

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S0092867420317530/pdf

publisherhttp://www.cell.com/article/S0092867420317530/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867420317530?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867420317530?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cell.2020.12.031

Fields of Study

RNA Research and Splicinginterferon and immune responsesRNA regulation and diseaseAdaptive ImmunityAnimalsApoptosisCell Line, TumorCytoplasmFemaleGene AmplificationHumansImmunityIntronsMiceMolecular Targeted TherapyProto-Oncogene Proteins c-mycRNA SplicingRNA, Double-StrandedSignal TransductionSpliceosomesTriple Negative Breast Neoplasms

MeSH Terms

AnimalsAntiviral AgentsCytoplasmFemaleGene AmplificationHumansImmunityIntronsRNA SplicingRNA, Double-StrandedSignal TransductionProto-Oncogene Proteins c-mycApoptosisSpliceosomesCell Line, TumorMiceAdaptive ImmunityMolecular Targeted TherapyTriple Negative Breast Neoplasms

Keywords

BiologySpliceosomeRNA splicingImmune systemCancer researchRNARNA silencingAlternative splicingCancerInnate immune systemBreast cancerTriple-negative breast cancerRNA interferenceImmunologyMessenger RNAGeneticsGeneMYCDouble-stranded RNAAnti-cancer ImmunityAntiviral ImmunityOncogenic StressViral MimicryRna Splicing In CancerSpliceosome-targeted Therapies

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697213.v1figshare

Additional file 1 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697213figshare

Additional file 2 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697216.v1figshare

Additional file 2 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697216figshare

Additional file 3 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697219.v1figshare

Additional file 3 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697219figshare

Additional file 4 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697222.v1figshare

Additional file 4 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697222figshare

Additional file 5 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697225.v1figshare

Additional file 5 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697225figshare

Additional file 6 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697228.v1figshare

Additional file 6 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697228figshare

Additional file 7 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697231.v1figshare

Additional file 7 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697231figshare

Additional file 8 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697234.v1figshare

Additional file 8 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697234figshare

Additional file 9 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697237.v1figshare

Additional file 9 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697237figshare

Additional file 10 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697240.v1figshare

Additional file 10 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

10.6084/m9.figshare.22697240figshare

Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer

FAIR Checklist

DataRank Breakdown

Authors (37)

Funding (10 grants)

Impact

Open Access

Topics

Linked Datasets (25)

Annotations (Europe PMC)